Tissue Plasminogen Activator: Reduction of Neurologic Damage After Experimental Embolic Stroke

Tissue plasminogen activator (tPA) has become available for pharmacologic use, and it appears to produce relatively fewer hemorrhagic complications than the previously available, less specific thrombolytic agents. We tested the effects of tPA in several models of embolic stroke and found that neurologic damage was reduced when the drug was administered as late as 45 minutes after cerebral embolic occlusion. The mechanism of therapeutic efficacy of tPA was probably thrombolysis. Drug-induced hemorrhages did not occur when therapy was started within four hours after the onset of vascular occlusion. These results suggest that tPA may be useful for thrombolytic therapy of embolic stroke if the drug is administered rapidly after the onset of vascular occlusion.

[1]  P. Lyden,et al.  Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. , 1988, Archives of neurology.

[2]  P. Lyden,et al.  A model for quantitative evaluation of embolic stroke therapy , 1987, Brain Research.

[3]  M. Sloan.  Thrombolysis and stroke. Past and future. , 1987, Archives of neurology.

[4]  H. Zeumer,et al.  Thrombolytic therapy in stroke: possibilities and hazards. , 1986, Stroke.

[5]  U. Degirolami,et al.  Tissue plasminogen activator reduces neurological damage after cerebral embolism. , 1985, Science.

[6]  Gary Halvorson,et al.  Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Verstraete M, Bory M, Erbel R, et al Lancet 842–847 Apr 13, 1985 , 1985 .

[7]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[8]  J. Rothrock,et al.  A new model of focal cerebral ischemia: validation and utility. , 1985, Bulletin of clinical neurosciences.

[9]  D. Collen,et al.  New approaches to thrombolytic therapy. , 1984, Arteriosclerosis.

[10]  D. Pennica,et al.  Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. , 1984, The Journal of pharmacology and experimental therapeutics.

[11]  M. Verstraete,et al.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. , 1983, The Journal of clinical investigation.

[12]  B. Siesjö,et al.  Thresholds in cerebral ischemia - the ischemic penumbra. , 1981, Stroke.

[13]  O. Matsuo,et al.  Comparison of the Relative Fibrinogenolytic, Fibrinolytic and Thrombolytic Properties of Tissue Plasminogen Activator and Urokinase in Vitro , 1981, Thrombosis and Haemostasis.

[14]  V. Marder,et al.  Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. , 1980, Annals of internal medicine.

[15]  W. Landau,et al.  Intracranial Bleeding Associated With Urokinase Therapy for Acute Ischemic Hemispheral Stroke , 1976, Stroke.

[16]  M. Raichle,et al.  A Pilot Study of Urokinase Therapy in Cerebral Infarction , 1976, Stroke.

[17]  K. Hossmann,et al.  Reversibility of ischemic brain damage. , 1973, Archives of neurology.

[18]  Waud Dr.  ON BIOLOGICAL ASSAYS INVOLVING QUANTAL RESPONSES , 1972 .

[19]  R. Adams,et al.  Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. , 1951, Journal of neuropathology and experimental neurology.